INCB018424 (Ruxolitinib)

Catalog No. A11041

INCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;
  • Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
  • Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
  • Kagoya Y, .et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2., Blood., 2014, Nov 6;124(19):2996-3006 PMID: 25217696
Catalog Num A11041
M. Wt 306.4
Formula C17H18N6
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 941678-49-5
Synonyms Ruxolitinib, INCB18424
SMILES C1CCC(C1)[[email protected]@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
INCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;
In vitro DMSO 61 mg/mL (199.1 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 32.64 mL 163.19 mL 326.37 mL
0.5 mM 6.53 mL 32.64 mL 65.27 mL
1 mM 3.26 mL 16.32 mL 32.64 mL
5 mM 0.65 mL 3.26 mL 6.53 mL

*The above data is based on the productmolecular weight 306.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.